AbbVie | ABBV - Sales Revenues

Stock Price
197.75
Daily Change
-0.96 -0.48%
Monthly
-7.21%
Yearly
2.81%
Q2 Forecast
194.46

AbbVie reported $16.62B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Abbott USD 11.16B 300M Mar/2026
ALKERMES USD 384.5M 9.7M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Infinity Pharmaceuticals USD 583K 148K Jun/2023
J&J USD 24.1B 500M Mar/2026
Medtronic USD 9B 39M Jan/2026
Merck USD 16.4B 880M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
UCB EUR 4.25B 764M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Zoetis USD 2.4B 0 Dec/2025